New Delhi: India’s indigenous COVID vaccine Covaxin has submitted its phase-3 clinical trial data to WHO on Wednesday, for its authorisation and global approval.
Sources state that Covaxin’s approval application will be taken up for consideration by WHO on June 23. As per WHO’s website, six vaccines – Pfizer, AstraZeneca, Sinopharm, Moderna, Sinovac and John & Johnson have been approved for global usage.
India’s other vaccine – Covishield has received Emergency approval by WHO.